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Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator that functions as a
master regulator of cellular and systemic oxygen homeostasis. It consists of two con-
stitutively produced subunits: HIF-1 and HIF-1. Under normoxic conditions
HIF-1 undergoes hydroxylation at specific prolyl residues which leads to an imme-
diate ubiquitination and subsequent proteasomal degradation of the  subunit. Addi-
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tionally, hydroxylation of an asparaginyl residue blocks the transcriptional activity
of HIF-1 due to inhibition of its interaction with co-activators. In contrast, under
hypoxic conditions, abolition of prolyl hydroxylation results in HIF-1 stabilization,
whereas the lack of asparaginyl hydroxylation allows the transcriptional activity. Ad-
ditionally, the transcriptional activity may be modulated by phosphorylation or re-
dox modification of HIF-1. Despite its name, HIF-1 is induced not only in response to
reduced oxygen availability but also by other stimulants, such as nitric oxide, various
growth factors, or direct inhibitors of prolyl and asparaginyl hydroxylases. There-
fore, it seems to be a crucial transcription factor elicited by a wide range of stresses
such as impaired oxygenation, inflammation, energy deprivation, or intensive prolif-
eration. However, the mechanisms of normoxic activation, as well as of oxygen sens-
ing, are not yet fully known. Further understanding of the processes that control
HIF-1 activity will be crucial for the development of new diagnostic and therapeutic
strategies.
Oxygen homeostasis is strictly controlled in
order to maintain intracellular levels of oxy-
gen within tight limits dictated by the require-
ment for O2 in many metabolic processes on
the one hand, and its high toxicity on the
other. The control occurs at the level of an en-
tire organism as well as at the level of a single
cell. It involves numerous mechanisms of reg-
ulation and adaptation to changes in O2 ten-
sion. At the cellular level, decreased O2 ten-
sion (hypoxia) leads to the activation of alter-
native metabolic pathways that do not require
molecular oxygen. The switch from aerobic
metabolism to anaerobic glycolysis is medi-
ated by the induction of glycolytic enzymes
and expression of glucose transporters. Addi-
tionally, the expression of various stress pro-
teins responsible for cell death or survival is
upregulated. Further adaptations which oc-
cur at the tissue and systemic levels lead to
the increase in O2 delivery. They include in-
duction of erythropoiesis (red blood cell pro-
duction), angiogenesis (new vessel forma-
tion), and hyperventilation. Among the vari-
ous upregulated proteins there is erythropoie-
tin (EPO), the main growth factor inducing
maturation of erythrocytes, and vascular en-
dothelial growth factor (VEGF), the major
mediator of angiogenesis and vascular perme-
ability. The hypoxia-dependent regulation of
these and other proteins (Table 1) occurs at
the transcriptional level and is mediated by
hypoxia-inducible transcription factor
(HIF-1).
Although the importance of HIF-1 in the in-
duction of the complex response to hypoxia is
widely appreciated, the molecular mecha-
nisms of HIF-1 activation remain unclear.
This review aims to summarize current
knowledge on HIF-1 regulation under hypoxic
and normoxic conditions.
HIF-1 TARGET GENES
The consensus DNA sequence for HIF-1 bin-
ding, 5-(A/G)CGTG-3, is common for many
genes upregulated by low oxygen tension
(Semenza et al., 1996). The list of known
genes activated by HIF-1 grows continuously.
It includes genes whose protein products act
both to maintain O2 homeostasis and to adapt
to changes in the oxygen concentration (Ta-
ble 1). The first group comprises of genes in-
volved in the development and functioning of
the vascular system. They either promote
angiogenesis (such as VEGF and its receptor
Flt-1) or modulate vascular tone (such as in-
ducible nitric oxide synthase, heme oxy-
genase-1, endothelin 1, adrenomedullin, and
1B-adrenergic receptor). The second group is
represented by genes whose protein products
induce erythropoiesis. Besides erythropoie-
tin, HIF-1 upregulates ceruloplasmin, trans-
ferrin, and transferrin receptor which facili-
tate the supply of iron to the erythroid tis-
sues. The third group consists of genes whose
products are involved in energy metabolism.
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Their cooperation leads to increased glucose
uptake and a switch to glycolysis as the main
source of energy. The fourth group comprises
genes whose products are responsible for cell
proliferation and viability. Besides these four
main sets of HIF-1-induced genes, there are
others also important in response to various
stresses (all references in Table 1).
HIF-1 STRUCTURE
HIF-1 is a heterodimer of two bHLH-PAS
proteins
Hypoxia-inducible factor-1 is a heterodimer
composed of the  and  subunits. Both of
them contain two characteristic domains: the
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Table 1. Genes upregulated by HIF-1.
basic helix-loop-helix (bHLH) domain and the
PAS (Per-AHR-ARNT-Sim) domain. The PAS
domain was termed as an acronym for the
first known members of the family: Dro-
sophila period (Per) and single-minded (Sim)
proteins and mammalian aryl hydrocarbon
receptor (AHR) and aryl hydrocarbon recep-
tor nuclear translocator (ARNT) proteins
(Wang et al., 1995a). It contains two internal
homology units, the A and B repeats, and is
involved in interaction between proteins.
PAS-proteins have been found in many spe-
cies, including prokaryotes, which indicates
their high evolutionary stability (Wang et al.,
1995a).
The bHLH domain, which is common for a
large number of transcription factors, is re-
quired for both protein dimerization and
DNA binding. In the case of HIF-1, the high-
est efficiency of heterodimerization is ob-
tained only if the bHLH and PAS domains are
intact (Jiang et al., 1996a). Moreover, the effi-
ciency of dimerization and DNA binding of in
vitro-translated HIF-1 and HIF-1 is weaker
than those isolated from a cell, suggesting
that one or both subunits may undergo
posttranslational modifications (Jiang et al.,
1996a).
HIF-1
HIF-1 is an 826-amino acid (120-kDa) pro-
tein (Fig. 1). In the N-terminal part it contains
the basic domain (aa 17–30), the he-
lix-loop-helix domain (aa 31–71), and the PAS
domain (aa 85–298) with PAS-A (aa 85–158)
and PAS-B (aa 228–298) repeats (Wang et al.,
1995a). Two transactivation domains, N-ter-
minal and C-terminal TADs (also termed
NAD and CAD), are localized in the C-termi-
nal half of HIF-1 (aa 531–575 and 786–826,
respectively; Pugh et al., 1997). Moreover, the
C-terminal part contains a domain responsi-
ble for degradation of HIF-1 under normoxic
conditions (Huang et al., 1998). This oxy-
gen-dependent degradation domain (ODD at
aa 401–603) contains two PEST-like motifs:
sequences rich in proline (P), glutamic acid
(E), serine (S), and threonine (T) (aa 499–518
and 581–600) common for many proteins
with a short half-life (less than 2 h)
(Rechsteiner & Rogers, 1996). The HIF-1
half-life under normoxic conditions is less
than 10 min and the protein is hardly detect-
able (Chun et al., 2002). Additionally, HIF-1
contains two nuclear localization signals:
N-NLS (aa 17–74) and C-NLS (aa 718–721).
The C-terminal NLS is crucial in the nuclear
import of HIF-1, whereas the N-terminal one
seems to be less important (Kallio et al.,
1998). Furthermore, alternative splice vari-
ants of HIF-1 and  have been observed
(Wang et al., 1995a; Gothie et al., 2000) and
both subunits contain multiple consensus
sites for protein phosphorylation (Wang et
al., 1995b).
HIF-1
HIF-1 was previously identified as aryl hy-
drocarbon nuclear receptor translocator
(ARNT), which heterodimerizes with aryl hy-
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Figure 1. Structure of HIF-1.
Numbers indicate the first and last amino-acid residues of each domain. The main domains are: basic helix-loop-he-
lix domain (bHLH), Per-AHR-ARNT-Sim homology domains (PAS-A and PAS-B), oxygen-dependent degradation
domain (ODD), and transactivation domains (N-TAD and C-TAD). Also position of PEST-like motifs and nuclear lo-
calization signals (NLS) is shown. Further description in the text.
drocarbon receptor (AHR) to form the func-
tional dioxin receptor. It has two isoforms
(774- and 789-aa that constitutes 92 or 94
kDa, respectively) that differ by the presence
of the sequence encoded by a 45-bp alterna-
tive exon (Wang et al., 1995a).
Additional HIFs
Two other members of the HIF-1 family
have been identified: HIF-2, also known as
endothelial PAS protein (EPAS1), HIF-like
factor (HLF), HIF-related factor (HRF), or a
member of PAS domain family 2 (MOP2); and
HIF-3. Both of them heterodimerize with
one of the members of the ARNT family:
ARNT (HIF-1), ARNT2, or ARNT3 (BMAL/
MOP3) (all references in Semenza, 2000b;
Wenger, 2002). The structure, regulation and
function of all HIFs seem to be similar. How-
ever, the expression of HIF-2, HIF-3,
ARNT2, and ARNT3 is tissue specific, which
suggests that they may play more specialized
roles (Semenza, 2000b).
OXYGEN-DEPENDENT HIF-1
REGULATION
Different levels of HIF-1 regulation
The regulation of HIF-1 activity concerns
mostly the  subunit and occurs at multiple
levels such as protein stabilization, post-
translational modifications, nuclear translo-
cation, dimerization, transcriptional activa-
tion, and interaction with other proteins.
Moreover, changes in mRNA expression
(Wang et al., 1995a; Wiener et al., 1996; Yu et
al., 1998) and alternative splicing (Gothie et
al., 2000) of both subunits have been ob-
served. Under normoxic conditions, however,
when HIF-1 and HIF-1 are constitutively
transcribed and translated, the abrogation of
HIF-1 activity results mainly from constitu-
tive HIF-1 degradation (Fig. 2).
Vol. 51 HIF-1: the knowns and unknowns of hypoxia sensing 567
Figure 2. Regulation of HIF-1 protein stability.
Under normoxic conditions HIF-1-prolyl hydroxylases (PHDs) hydroxylate Pro 402 and 564 (P) within the ODD do-
main. After prolyl hydroxylation von Hippel-Lindau tumor suppressor proteins (pVHLs) bind to the ODD domain
and recruit other proteins of E3 ubiquitin ligase complex. HIF-1 is subsequently ubiquitinated and degraded by
the 26S proteasome. Under hypoxic conditions HIF-1-prolyl hydroxylases are inactive which prevents binding of
pVHL. Therefore, HIF-1 escapes ubiquitination and proteasomal degradation, and can be transported to the nu-
cleus where, after dimerization with HIF-1, it stimulates target genes transcription.
HIF-1 degradation
Ubiquitination
Under normoxic conditions HIF-1 is sub-
jected to ubiquitination and degradation by
the 26S proteasome proteolysis (Kallio et al.,
1999). In HIF-1 ubiquitination the major
role is played by the von Hippel-Lindau tumor
suppressor protein (pVHL), whose -domain
interacts directly with the ODD domain of
HIF-1 (Bonicalzi et al., 2001). The inactiva-
tion of pVHL is associated with the von
Hippel-Lindau disease, which is a hereditary
cancer syndrome characterized by the devel-
opment of highly vascularized tumors with
constitutive HIF-1 expression (Ivan et al.,
2001). pVHL acts as the substrate recognition
component of the E3 ubiquitin ligase protein
complex and after binding to HIF-1 it re-
cruits elongins B and C, cullin 2, and Rbx1
(reviewed in Semenza, 2001).
The interaction between pVHL and HIF-1
is oxygen-dependent: pVHL associates with
ODD under normoxic but not under hypoxic
conditions, thus the degradation does not oc-
cur during hypoxia (Maxwell et al., 1999). The
interaction of pVHL with HIF-1 depends on a
posttranslational modification of HIF-1,
which was identified as an oxygen- and
iron-dependent prolyl hydroxylation (Ivan et
al., 2001). The binding of pVHL to the ODD
domain, and therefore the ubiquitination of
its N- and C-terminal part (aa 390–417 and
549–582, respectively), must be preceded by
the hydroxylation of proline residues (Pro
402 in the N-terminal part and Pro 564 in the
C-terminal part of ODD, Fig. 2). These resi-
dues are embedded in the conserved amino
acid motif, LXXLAP, in which Leu 562
strongly facilitates the hydroxylation of Pro
564 (Ivan et al., 2001).
HIF-1 prolyl hydroxylases
The hydroxylation of the proline residues in
the ODD domain of HIF-1 is catalyzed by
HIF-1 prolyl 4-hydroxylases, members of the
Fe(II)- and 2-oxoglutarate-dependent dioxy-
genase superfamily. Their activity, however,
is distinct from the activity of procollagen
prolyl hydroxylases, which belong to the same
superfamily (Bruick & McKnight, 2001;
Jaakkola et al., 2001). The prolyl hydroxylase
responsible for HIF-1 hydroxylation was
first identified as a product of egl-9 gene after
searching Caenorhabditis elegans genome da-
tabase (Epstein et al., 2001). Egl-9 mutant
worms, similarly to vhl-1 mutants, constitu-
tively expressed HIF-1. Later three EGL-9
homologues in mammals were identified and
designated PHD (PH domain containing pro-
tein) 1, 2, and 3. They are also termed HPHs
(HIF-1 prolyl hydroxylases) 3, 2, and 1, re-
spectively. They differ in intracellular local-
ization: PHD1 was detected exclusively in the
nucleus, PHD2 — in the cytoplasm, whereas
PHD3 in both nucleus and cytoplasm (Metzen
et al., 2003a). Additionally, the existence of a
fourth PHD has been described (Oehme et al.,
2002). Each of them hydroxylates Pro-564 in
HIF-1, whereas only PHD1 and PHD2
hydroxylate Pro-402. Molecular oxygen is a
substrate of these enzymes, while carbon di-
oxide and succinate are by-products. During
hypoxia, or in case of a lack of Fe(II) or
2-oxoglutarate, prolyl hydroxylases cease to
function, thus HIF-1 does not undergo deg-
radation (reviewed in Semenza, 2001).
HIF-1 activation
To obtain full transcriptional activity HIF-1
must bind to the DNA target sequence and re-
cruit transcriptional cofactors. This phase
also undergoes hypoxia-dependent regula-
tion. The role of HIF-1 transactivation do-
mains (TADs) is to recruit the transcriptional
coactivator complexes to the promoters of
HIF-1 target genes. The central integrating
coactivator p300/CBP interacts through its
CH1 (cysteine-histidine-rich) domain with
HIF-1 TADs (Gu et al., 2001) and recruits
the accessory coactivators like histone
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acetylotransferases SRC-1, TIF-2, and redox
factor Ref-1 (Ema et al., 1999).
The molecular mechanism of activation of
the TAD domains was recently discovered.
Under normoxic conditions the highly con-
served asparagine residue within the C-TAD
domain (Asn 803) is hydroxylated (Lando et
al., 2002a) which results in the silencing of
transactivation domains (Fig. 3). The enzyme
that hydroxylates the Asn residues is also a
member of the Fe(II)- and 2-oxoglutarate-de-
pendant superfamily of dioxygenases, thus it
is blocked by the inhibitors of 2-oxogluta-
rate-dependent dioxygenases such as dime-
thyloxalylglycine (DMOG) and Fe(II) chela-
tors. Treatment of cells with DMOG or iron
chelators as well as replacing the critical Asn
residue with Ala result in activation of C-TAD
even at normoxia (Lando et al., 2002a). There-
fore, p300/CBP interacts with C-TAD only
when the Asn is nonhydroxylated which en-
ables the assembly of transcriptional co-
activator complex, whereas the hydroxylation
of Asn during normoxia silences C-TAD do-
main by preventing its interaction with
p300/CBP. The asparaginyl hydroxylase that
modifies HIF-1 was recently identified as
the previously known factor inhibiting HIF-1
(FIH-1) (Lando et al., 2002b). The final evi-
dence that both residues, Pro within the ODD
and Asn within the C-TAD, are necessary for
the full activation of HIF-1 was provided by
an experiment in which either critical Pro, or
Asn, or both were replaced by Ala (Lando et
al., 2002a). Replacement of Pro within the
ODD domain resulted in a stable protein even
under normoxia which, however, exhibited
low transcriptional activity at normoxia and
high transcriptional activity at hypoxia. Re-
placement of the critical Asn within the
C-TAD domain does not influence protein ac-
tivity in comparison to wild-types proteins,
because, despite the active C-TAD domain,
the protein is unstable at normoxia. Finally,
the double amino acid substitution resulted in
nearly full activity of the protein at normoxia
(Lando et al., 2002a).
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Figure 3. The role of prolyl and asparaginyl hydroxylation in the stabilization and activation of HIF-1.
Under normoxic conditions specific prolyl (P) residues within the oxygen-dependent degradation domain (ODD)
and asparaginyl (N) residues within the COOH-terminal transactivation domain (C-TAD) are hydroxylated by re-
spective hydroxylases. The hydroxylation of prolines enables binding of pVHLs and thus constitutes a signal for
proteasomal degradation. The hydroxylation of asparaginyl (N) residues blocks binding of transcriptional
coactivator (p300/CBP) and subsequently inhibits transcriptional activity of HIF-1. In contrast, under hypoxic con-
ditions HIF-1 escapes proteasomal degradation because of abolition of prolyl hydroxylation and may interact with
p300/CBP due to inhibition of asparaginyl hydroxylation.
Other levels of HIF-1 regulation
Nuclear localization of HIF-1
The dimerization of the HIF-1  and  sub-
units occurs in the nucleus and is necessary
for the DNA binding and subsequent activa-
tion of transcription (Kallio et al., 1997). In
contrast to HIF-1 which is present in the nu-
cleus regardless of oxygen levels, nuclear
translocation of HIF-1 is correlated with
HIF-1 activity. Consequently, it was sug-
gested that this translocation could be
upregulated by hypoxia (Kallio et al., 1998).
However, when HIF-1 is overexpressed the
translocation occurs even under normoxic
conditions. Therefore, this process seems to
be hypoxia-independent and the nuclear frac-
tion of HIF-1 may simply reflect the overall
level of this protein in the cell (Hofer et al.,
2001).
HIF-1 DNA binding
After the stabilization of the  subunit, nu-
clear translocation, and dimerization, HIF-1
binds to its consensus binding site (HBS,
HIF-1 binding site) within the hypoxia re-
sponse element (HRE) (Semenza et al., 1996).
The core sequence of HBS is (A/G)CGTG.
HRE may be located within either promoter
or enhancer regions (5-flanking, 3-flanking,
or intervening) of target genes (Fig. 4, refer-
ences in Table 1). Generally, HBS is the mini-
mal sequence necessary for HIF-1 binding.
However, the structure of HRE, methylation
of the cytosine residue within HBS, or pres-
ence of additional transcription factors may
influence HIF-1-induced response. Addition-
ally, in the majority of hypoxia-induced genes
HRE contains HIF-1 ancillary sequence
(HAS), which is located 8–9 nt down- or up-
stream of HBS and is necessary for HIF-1-me-
diated transcription activation (Kimura et al.,
2001). HAS is an imperfect inverted repeat of
HBS, thus the secondary structure of HRE
seems be crucial for its activatory function
(Fig. 5). It was also shown that HAS recruits
protein complexes distinct from HIF-1
(Kimura et al., 2001).
Furthermore, efficient gene activation fre-
quently requires recruiting of more than one
HIF-1 or binding of additional transcriptional
factors, which are not hypoxia-dependent.
Two or three adjacent HBSs were found in
some genes encoding glycolytic enzymes, glu-
cose transporter 1, and transferrin. There is
also a binding site for the ATF-1/CREB-1 fac-
tor (activating transcription factor-1/cAMP-
response element-binding protein-1) in the
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Figure 4. The localization of hypoxia response element (HRE) in various hypoxia-induced genes.
HRE (black rectangle) may be located within either 5-flanking (VEGF and transferrin) or 3-flanking (EPO)
enhancer regions, or within the promoter (NOSII) of target genes.
HRE of lactate dehydrogenase A gene, for
AP-1 (activator protein-1) binding factor in
VEGF gene, and for the HNF-4 (orphan recep-
tor hepatic nuclear factor-4) in the erythropoi-
etin gene (references in Wenger, 2002). All
these transcription factors modulate HIF-1
response. Such a requirement for additional
transcription factors may (i) amplify hypoxic
response in particular conditions, (ii) vary re-
sponses of distinct tissues to the hypoxia, and
(iii) enable diverse induction of distinct target
genes.
Another possible level of regulation may be
the CpG methylation of the cytosine residue
within HBS. Although, in the majority of
HIF-1 target genes it remains unmethylated
as it is located in the methylation-free CpG is-
lands, the HBS of the erythropoietin gene
might undergo methylation, which inhibits
HIF-1 binding (Wenger et al., 1998). To pre-
vent methylation, HBS is at normoxia occu-
pied by other DNA binding factors (reviewed
in Wenger, 2002). It might also be hypothe-
sized that methylation of HBS may constitute
a mechanism of cell-specific regulation of
hypoxia-induced gene expression. Interest-
ingly, human macrovascular endothelial cells
do not release VEGF either under normoxic
conditions (Frick et al., 2003) or in response
to hypoxia (unpublished data). In contrast, in
human microvascular endothelial cells
(Józkowicz et al., 2004) and smooth muscle
cells (Dulak et al., 2002) hypoxia potently
modulates VEGF production. These data
suggest that the response to hypoxia is cell
type specific.
Molecular mechanism of oxygen sensing
Although the mechanisms of HIF-1 stabili-
zation and activation are already known, the
signaling pathways that lead to the inhibition
of prolyl and asparaginyl hydroxylases re-
main unclear. The requirement of molecular
oxygen as a substrate for these enzymes could
explain the loss of HIF-1 degradation under
hypoxic conditions. This assumption, how-
ever, appears to be oversimplified. It has been
shown that collagen prolyl hydroxylases are
active in hypoxic cells and that maximal
HIF-1 stabilization occurs under 0.5% O2
concentration rather than under anoxia,
which would not be possible if prolyl
hydroxylases were direct oxygen sensors
(Jiang et al., 1996b). Moreover, earlier stud-
ies provided evidence that other signaling
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Figure 5. Human hypoxia response element (HRE) in VEGF, EPO, glucose transporter-1 (GLUT-1), and
lactate dehydrogenase A (LDHA) genes (Kimura et al., 2001).
HRE, besides the HIF-1 binding site (HBS), contains the HIF-1 ancillary sequence (HAS), which is located 8–9 nt
down- or upstream of HBS and constitutes an imperfect inverted repeat of HBS.
pathways, such as ROS-, protein phos-
phorylation-, and nitrosylation-dependent
pathways are involved in oxygen sensing.
Therefore, many models of intracellular
oxygen sensing have been considered.
A hemoprotein as an oxygen sensor
The initial hypothesis suggested that the
role of oxygen sensor is mediated by an un-
known protein containing heme as a pros-
thetic group. The putative role of heme,
bound either to HIF-1 PAS domains or to a
distinct sensor hemoprotein, was suggested
because of the fact that HIF-1 activation is in-
duced not only by the lack of molecular oxy-
gen but also by Fe(II) chelators, such as
desferrioxamine (Wang et al., 1993), and also
by some transient metals that could replace
Fe(II) in heme (Huang et al., 1997). However,
currently these observations seem to confirm
the iron-dependence of prolyl and asparaginyl
hydroxylases rather than hemoproteins
acting as the oxygen sensor.
ROS-dependent signaling pathways
Two opposing models postulate signaliza-
tion by changes in the cellular levels of reac-
tive oxygen species (ROS) (reviewed in
Semenza, 2000c; Michiels et al., 2002). The
first of them assumes that ROS are continu-
ously produced by an unknown NADPH
oxidase that reduces O2 to superoxide anion
(O2
–) which is subsequently converted to hy-
drogen peroxide (H2O2) by superoxide
dismutase (SOD). According to this model the
reduction of molecular oxygen concentration
would be followed by the reduction of ROS
levels, and therefore a decrease in ROS gener-
ation would be a direct or indirect signal for
HIF-1 activation (Fig. 6). The experiments
confirming this hypothesis showed: (i) de-
creased ROS production under hypoxic condi-
tions, (ii) suppression of HIF-1 target genes
by exogenous H2O2 in hypoxia, (iii) the pres-
ence of a non-mitochondrial cytochrome
b-containing NADPH oxidase that could re-
spond to oxygen levels (references in Michiels
et al., 2002), and (iv) induction of HIF-1 target
genes in the presence of exogenous catalase
or antioxidants (Salceda & Caro, 1997). How-
ever, some observations were inconsistent
with this hypothesis. A nonspecific inhibitor
of NADPH oxidases (diphenylene iodonium,
DPI) blocked HIF-1 activation in response to
hypoxia (Gleadle et al., 1995) and HIF-1 activ-
ity was sustained in cells deficient in a sub-
unit of NADPH oxidase (Archer et al., 1999).
Moreover, some experiments indicated that
the production of ROS was increased rather
than decreased during hypoxia (Chandel et
al., 1998).
The second model concerning ROS-depend-
ent pathway is diametrically opposed to the
previous one as it assumes that hypoxia re-
sults in an increased generation of ROS by
mitochondria, which constitutes the signal to
HIF-1 stabilization (Fig. 7). According to
this model under hypoxic conditions the con-
sumption of oxygen at cytochrome c oxidase
(mitochondrial complex IV) is lower and elec-
trons accumulate at preceding complexes.
Such an accumulation leads to increased gen-
eration of ROS at complex III. Compatibly
with this theory inhibitors of complexes I and
III blocked the induction of HIF-1 activity at
hypoxia (due to inhibition of ROS produc-
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Figure 6. Model I of ROS-dependent hypoxia sig-
nal transduction.
According to this model hypoxia results in decreased
reactive oxygen species (ROS) generation, which leads
to HIF-1 stabilization. The same effect is observed in
the presence of antioxidants and catalase (Cat).
tion), whereas inhibitors of complex IV were
able to induce HIF-1-dependent transcription
at normoxia (due to induction of ROS genera-
tion) (Chandel et al., 1998). Another evidence
that mitochondrial complex III acts as an oxy-
gen sensor was shown in 0 Hep3B cells, lack-
ing the functional respiratory chain, in which
the induction of HIF-1 did not occur under
hypoxic conditions (Chandel et al., 1998).
Moreover, the substrate of complex II
(succinate) restored hypoxic response in cells
with a defect in complex I (Agani et al., 2000).
Consistent with this theory are also our re-
sults showing that overexpression of SOD,
leading to increased production of H2O2, in-
duces HIF-1-dependent VEGF expression
(Grzenkowicz-Wydra et al., 2004).
However, these findings were not confirmed
in other experiments on 0 cell lines cultured
under severe hypoxic conditions (0.1% O2)
(Vaux et al., 2001) or after exposure to cobalt
chloride or desferrioxamine instead of
hypoxia (Chandel et al., 1998). The explana-
tion of the contradictory results of Chandel et
al. (1998), and Vaux et al. (2001) may lie in
different mechanisms of oxygen sensing in
the case of anoxia and hypoxia. Prolyl and
asparaginyl hydroxylases, which use molecu-
lar oxygen as a substrate, act as direct oxygen
sensors in the total absence of oxygen
(Schroedl et al., 2002). Similarly, des-
ferrioxamine and cobalt chloride are direct in-
hibitors of the hydroxylases. Thus, at anoxia
or after treatment with desferrioxamine or
cobalt chloride, stabilization of HIF-1 occurs
independently of ROS generation and the
presence of functional electron transport
chain is not necessary. This hypothesis ex-
plains why inhibitors of complex I prevent
hypoxia-induced but not desferrioxamine- or
anoxia-induced accumulation of HIF-1
(Schroedl et al., 2002). In contrast, in the
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Figure 7. Model II of ROS-dependent hypoxia signal transduction.
According to this model hypoxia results in an increased generation of reactive oxygen species (ROS) due to attenu-
ation of cytochrom c oxidase (mitochondrial complex IV) activity. The generation of ROS is mediated by complex
III at which, in the absence of functional cytochrome c oxidase (due to hypoxia or in the presence of complex IV in-
hibitors), electrons are accumulated. High levels of ROS induce HIF-1 stabilization, whereas low levels lead to
HIF-1 degradation. Low levels of ROS are maintained either when the electron transport chain is fully functional
(normoxia) or when electrons do not reach complex III (in the presence of inhibitors of complex I and II, or III).
hypoxia-mediated HIF-1 stabilization addi-
tional intracellular signaling, including
phosphorylation- and ROS-dependent path-
ways, is required (Schroedl et al., 2002). The
preservation of hypoxia-induced stabilization
of HIF-1 in cells with a defect in electron
transport chain (Vaux et al., 2001) may have
resulted either from the presence of marginal
complex I and III activity, sufficient to gener-
ate ROS, or from anoxic rather than hypoxic
conditions (0.1% O2) used in the experiments.
It is possible that signals induced by hypoxia,
as well as signals from some cytokines,
vasoactive hormones, and nitric oxide (see be-
low) lead to the inhibition of proline
hydroxylation (Fig. 8).
Phosphorylation cascades
Initial studies indicated that the activation
of HIF-1 involves protein phosphorylation
(Wang et al., 1995b). This process might be
mediated by several different protein kinase
pathways. First, the p42/p44 (Erk2/Erk1)
mitogen-activated protein kinases (MAPKs)
are able to phosphorylate HIF-1 (Richard et
al., 1999). This modification, however, en-
hances HIF-1 activity but is not involved in
HIF-1 stabilization. Thus, this is rather the
way in which growth factors modify HIF-1
function as many of them act via the receptor
tyrosine kinaseRas/RafMEK (mitogen-ac-
tivated kinase kinase)MAPK pathway (re-
viewed in Wenger, 2002). The second path-
way able to upregulate HIF-1 activity involves
the receptor tyrosine kinasePI3K (pospha-
tidylinositol-3 kinase) prolyl-4-hydroxylases
(protein kinase B)FRAP (FKBP-rapamycin
associated protein) pathway. Some studies
showed that inhibition of the PI3K or AKT
kinases impairs HIF-1-dependent gene ex-
pression (references in Wenger, 2002). More-
over, loss of PTEN (phosphatase and tensin
homolog deleted on chromosome ten) activ-
ity, which is a tumor suppressor protein and a
negative regulator of PI3K, results in in-
creased HIF-1 expression (Zundel et al.,
2000). Finally, FRAP can stimulate HIF-1
expression even under normoxic conditions
(Zhong et al., 2000). Additionally, the involve-
ment of ROS-dependent p38 MAP kinase
pathway has been suggested because inhibi-
tion of HIF-1 activity by p38 kinase blockers
was observed (Gorlach et al., 2001).
Other signaling pathways
Other suggested signaling pathways con-
cern redox-dependent regulation and protein
N-nitrosylation. For example, it was shown
that reduction of cysteine within C-TAD en-
hances HIF-1 trans-activation by enabling
the interaction with CBP. This reduction is
provided by the system: thioredoxin/the re-
dox factor Ref-1 (Ema et al., 1999). Co-ex-
pression of Ref-1 and thioredoxin enhanced
the transactivation by C-TAD, but not by
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Figure 8. Prolyl and asparginyl hydroxylases function as direct (anoxia) or indirect (hypoxia) oxygen
sensors.
N-TAD, in a hypoxia-dependent manner. Ad-
ditionally, upon hypoxic conditions, thio-
redoxin was found to be translocated to the
nucleus where it can interact with Ref-1
(Ema et al., 1999).
HIF-1 negative regulation
Several negative feedback regulatory path-
ways that could limit the response to hypoxia
have been proposed (reviewed in Wenger,
2002). The downregulation of HIF-1 might
occur on the level of transcription, transla-
tion, protein stabilization, and/or protein ac-
tivation. Responsible for the latter could be
Cited2 (also named p35srj), a member of the
CBP/p300-interacting transactivators with a
glutamic acid and aspartic acid-rich tail.
Cited2 competes with HIF-1 in binding to the
cysteine-histidine-rich (CH1) region of p300
and CBP (Leung et al., 1999). Notably, Cited2
expression is induced by HIF-1 (Bhattacharya
et al., 1999).
Recently it was shown that the down-
regulation occurs also at the level of HIF-1
stabilization as HIF-1 induces synthesis of
prolyl hydroxylases which enable rapid
HIF-1 hydroxylation and degradation dur-
ing reoxygenation (D’Angelo et al., 2003).
Also some anti-inflammatory factors could
act through the inhibition of the HIF-1 path-
way. We recently showed that under hypoxic
conditions prostaglandin-J2 attenuates VEGF
expression by inhibition of HIF-1 activity
(Józkowicz et al., 2004). Furthermore, heme
oxygenase-1, which is a stress inducible en-
zyme that degrades heme to carbon monox-
ide, iron ions, and biliverdin, could enhance
activity of prolyl and asparaginyl hydroxy-
lases by an increased release of iron.
Biliverdin and its derivate, bilirubin, scaven-
gers of peroxyl radicals, could also modulate
HIF-1 stability due to the attenuation of re-
active oxygen species generation. On the
other hand, it was observed that HO-1 over-
expression enhances VEGF synthesis (re-
viewed in Dulak et al., 2004).
Interaction between HIF-1 and p53
There are many similarities between the two
transcription factors: HIF-1 and the tumor
suppressor p53. Under hypoxic conditions
both proteins accumulate and gain their
transcriptional activity which requires re-
cruitment of p300 as a co-activator. More-
over, under normoxic conditions p53, simi-
larly to HIF-1, is ubiquitinated by E3 ligase
(MDM2 for p53) and subsequently degraded
by 26S proteasome (Giaccia et al., 1998). It
was observed that the loss of p53 activity re-
sults in an increased accumulation of HIF-1
under hypoxic conditions (Ravi et al., 2000).
This relationship was explained by the obser-
vation that p53 binds to HIF-1 and recruits
the MDM2 ubiquitin ligase which preferably
targets HIF-1 for degradation. Thus, in the
case of prolonged anoxic conditions, p53 can
act as a negative regulator of HIF-1 in two
ways. First, it inhibits HIF-1 activity by com-
petitive binding of p300 (Schmid et al., 2003),
and second, the interaction between p53 and
HIF-1 results in HIF-1 degradation (Ravi et
al., 2000). Such cooperation explains the
angiogenic switch that occurs during tumori-
genesis in case of p53 mutation.
HIF-1 natural inhibitors
The natural inhibitors of HIF-1 identified so
far are mainly splice variants of the  subunit
and thus are able to act as HIF antagonists.
The first of them, inhibitory PAS protein
(IPAS) is a HIF- without the transactivation
domain. High levels of IPAS were indicated in
the corneal epithelium of the eye where
HIF-dependent angiogenesis is significantly
impaired (Makino et al., 2001). Other poten-
tial HIF-1 antagonists are: the zinc-inducible
isoform lacking exon 12 (HIF-1Z) and the
dominant-negative HIF-1 isoform lacking
exons 11 and 12. In addition, an antisense
RNA specific for the 3' untranslated region of
HIF-1 was identified (references in Wenger,
2002).
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NON-HYPOXIC ACTIVATION OF HIF-1
AND MODULATORS OF HIF-1
ACTIVITY
Interestingly, an increasing number of stud-
ies indicate that HIF-1 stabilization might
occur in a hypoxia-independent manner. The
inducers of HIF-1 activity that act independ-
ently of O2 levels may be divided into several
groups. The first group consist of direct inhib-
itors of prolyl and asparaginyl hydroxylases
such as iron chelators, iron replacing mole-
cules, and analogs of 2-oxoglutarate. The sec-
ond group is represented by various hor-
mones and growth factors. Also hallmarks of
inflammation such as proinflammatory
cytokines, nitric oxide, increased tempera-
ture, or mechanical stress, may induce HIF-1
activity.
Direct inhibitors of prolyl hydroxylases
Transition metal ions, such as cobalt and
nickel, induce HIF-1 stabilization under
normoxic conditions. Initially this effect was
thought to confirm the hypothesis of a heme
protein acting as a putative oxygen sensor
(Huang et al., 1997). Recently, however, it
was suggested that transition metals could in-
hibit prolyl hydroxylases by substituting the
ferrous ion coordinated by PHDs (Epstein et
al., 2001). Another well-known activator of
HIF-1, desferrioxamine (Wang et al., 1993),
could also inactivate PHDs by removal of iron
from their catalytic domains. Furthermore,
compounds competing with 2-oxoglutarate
such as N-dimethyl-oxalylglycine (DMOG), a
2-oxoglutarate analog, are also able to inhibit
PHDs activity (Jaakkola et al., 2001).
Vasoactive hormones and cytokines
The induction of VEGF expression in vascu-
lar smooth muscle cells (VSMC) by vasoactive
hormones like angiotensin II and thrombin is
mediated through the activation of HIF-1
(Richard et al., 2000). Two separate pathways
are responsible for this hypoxia-independent
induction of HIF-1 in VSCM. The first leads to
an increase in HIF-1 gene transcription,
whereas the second results in an increase in
translation of HIF-1 mRNA. The central role
in both pathways belongs to the diacyl-
glycerol-sensitive protein kinase C (PKC). It
was also shown that the increase in HIF-1
translation by angiotensin II is mediated by
ROS-dependent activation of the phospha-
tidylinositol-3 kinase (PI3K) pathway (Page et
al., 2002). Together these two pathways in-
crease HIF-1 in VSMC to levels that surpass
hypoxic induction.
Also some growth factors such as insulin, in-
sulin-like growth factor 1 and 2, epidermal
growth factor, fibroblast growth factor 2,
platelet-derived growth factor, transforming
growth factor 1, and inflammatory cytokines
such as interleukin-1, or tumor necrosis fac-
tor , (all references in Wenger, 2002) can
evoke HIF-1 activation under normoxic condi-
tions. Most of them act through the tyrosine
kinase receptorPI3KAKTFRAP path-
way. This growth factor-dependent HIF-1 acti-
vation is important in tumorigenesis as the
overexpression of some growth factors may
cause HIF-1-mediated induction of intra-
tumoral angiogenesis.
Nitric oxide
HIF-1 induces nitric oxide production
through the enhancement of inducible nitric
oxide synthase transcription (Table 1). Con-
versely, NO affects the accumulation and ac-
tivity of HIF-1. Initial studies focusing on the
NO influence on HIF-1 activity showed that
under hypoxic conditions, or after treatment
with CoCl2, NO inhibits HIF-1 stabilization
and transcriptional activation (Liu et al.,
1998; Sogawa et al., 1998; Huang et al., 1999).
On the other hand, it was indicated that un-
der normoxic conditions diverse NO donors
(with the exception of sodium nitroprusside,
SNP) or endogenously produced NO (by in-
ducible or endothelial nitric oxide synthase,
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NOS2 and NOS3, respectively) causes HIF-1
stabilization and activation of its target genes
(Kimura et al., 2000; Dulak et al., 2000;
Sandau et al., 2001a; 2001b; Józkowicz et al.,
2001; Dulak & Józkowicz, 2003b). Normoxic
NO-induced upregulation of HIF-1 occurred
through the PI3K/Akt pathway (Sandau et
al., 2001b; Brüne et al., 2001; Natarajan et al.,
2003) and was independent of soluble
guanylyl cyclase (sGC) activity (Brüne et al.,
2001). The type of the NO donor and its con-
centration used in experiments seem to be
crucial for the results obtained. The inhibi-
tory effect of SNP may be evoked by toxic
by-products of its decomposition such as
cyanides and iron ions which probably sur-
pass the effect of NO (Dulak et al., 2000;
Józkowicz et al., 2001).
NO and PHDs
Recently it was reported that the NO-medi-
ated activation of HIF-1 at normoxia is caused
by attenuation of prolyl hydroxylation
(Metzen et al., 2003b) and, therefore, PHDs
might constitute direct or indirect targets of
NO. An interaction between NO and iron
could constitute a way of affecting prolyl
hydroxylation as NO directly binds to the fer-
rous ion in heme or non-heme iron-containing
proteins. Prolyl hydroxylases contain Fe(II)
in their catalytic domains, thus NO could
compete with molecular oxygen for the cata-
lytic site and subsequently inhibit enzyme
function (Metzen et al., 2003b). This hypothe-
sis, however, does not explain why NO inhib-
its hypoxia-induced HIF-1 accumulation.
Helpful in searching for the answer could be
the fact that NO down-regulates HIF-1 in
hypoxia by activation of PHDs in cytoplasmic
extracts (Wang et al., 2002), although this ef-
fect has not been confirmed by in vitro pro-
tein interaction assays (Metzen et al., 2003b).
Therefore, activation of PHDs by NO might
be caused by cytoplasmic components such as
protein phosphorylation cascades or/and
ROS-dependent signaling pathways. Re-
cently, however, it was reported that NO do-
nor, NOC18, induces HIF-1 synthesis at
normoxia, whereas neither hydroxylation nor
stabilization of HIF-1 is influenced. Instead,
it was shown that this effect depends on the
PI3 and MAP kinases pathways (Kasuno et
al., 2004).
NO and ROS
On the other hand, NO as a free radical re-
acts rapidly with ROS, particularly in a diffu-
sion-controlled fashion with superoxide anion
to create peroxynitrate, one of the most reac-
tive compounds in nature. If hypoxia acti-
vates HIF-1 through the increase in mitochon-
drial ROS generation, NO would inhibit HIF-1
activation by attenuation of ROS levels. To
confirm this hypothesis it was shown that NO
blocks HIF-1 stabilization in the presence of
superoxide anion donors or H2O2 (Sandau et
al., 2001b). Thus ROS and NO might be able
to induce HIF-1 activity but, when present to-
gether, they may react to form compounds
such as peroxynitrite that lacks this property
and might cause HIF-1 degradation.
Carbon monoxide
Initially it was reported that carbon monox-
ide (CO) inhibits hypoxia-induced HIF-1 ex-
pression, HIF-1 DNA binding, and HIF-1
transcriptional activity (Huang et al., 1999).
Such a correlation would be consistent with
the hypothesis of a heme protein acting as an
oxygen sensor. However the concentrations
of CO used in those experiments were very
high (up to 80%) and therefore non-physiologi-
cal. On the contrary, it is possible that CO, as
an inhibitor of mitochondrial complex IV,
could lead to an increase in ROS generation
and, therefore, induce HIF-1 accumulation.
We have shown that low (1% or lower) concen-
trations of CO strongly induce VEGF expres-
sion in vascular smooth muscle cells (Dulak et
al., 2002) and in endothelial cells (Józkowicz
et al., 2003; reviewed in Dulak & Józkowicz,
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2003a). Another interesting hypothesis was
proposed after the discovery that mammalian
neuronal PAS domain protein 2 (NPAS2), a
bHLH-PAS transcription factor involved in
regulation of circardian cycle, is regulated not
only by the NADPH/NADP ratio but also by
carbon monoxide (Dioum et al., 2002). Incor-
poration of CO into hemes which are bound to
the PAS domains of NPAS2 inhibits
NPAS2-BMAL1 heterodimerization and, sub-
sequently, its transcriptional activity. The
NPAS2 binding sequence, CACGTG (Rutter
et al., 2001), may be recognized by HIF-1, thus
reciprocal relationship between these two
transcription factors is possible and requires
further studies.
Mechanical and thermal stress
It has been reported that HIF-1 is present
in the nuclei of cardiac myocytes in
non-hypoxic myocardium (Kim et al., 2002).
This upregulation of HIF-1 occurs as a result
of a wall stretch and is mediated by the
PI3KAKTFRAP pathway. A similar effect
was observed in aortic VSMC where hyper-
tension induced HIF-1 accumulation
(Kuwahara et al., 2002). Therefore, HIF-1
seems to be responsible not only for the adap-
tation to hypoxia but also for the adaptation
to mechanical stress.
It was also indicated that HIF-1 accumula-
tion might be evoked by exposure to in-
creased temperature. This effect seems to be
mediated by direct protein stabilization that
involves the heat shock protein HSP90 and is
hypoxia-independent (Katschinski et al.,
2002).
CONCLUSIONS
Undoubtedly, HIF-1 plays the leading role in
the induction of complex response to various
stresses and thus contributes to the mainte-
nance of cellular and systemic homeostasis.
This function gives HIF-1 a major importance
in development, physiology, and patho-
physiology. The central role in the regulation
of HIF-1 activity belongs to prolyl and aspar-
aginyl hydroxylases, which function coopera-
tively as direct or indirect oxygen sensors.
The question is why HIF-1 activity is con-
trolled by two independent processes. The an-
swer might be that multiple levels of the regu-
lation enable graded responses to subtle
changes in O2 concentration and ensure tight
control of the hypoxic response pathway
(Bruick & McKnight, 2002).
The analysis of HIF-1 expression pattern
and the modulation of HIF-1 activity may
bring new diagnostic and therapeutic ap-
proaches in many diseases such as cancer and
vascular disorders (reviewed in Semenza
2000a). It is possible that inhibition of HIF-1
could suppress intratumoral angiogenesis
and thus attenuate cancer growth. Addition-
ally, it was observed that Hif1a+/– mice had
significantly weaker responses to chronic
hypoxia such as reduced polycythemia, right
ventricular hypertrophy, and pulmonary hy-
pertension (Yu et al., 1999). Thus in case of
chronic lung disease local downregulation of
HIF-1 could be useful in treating or prevent-
ing these disorders. In contrast, in the case of
myocardial ischemia or other ischemic disor-
ders induction of HIF-1 expression could pre-
vent ischemic tissues from permanent dam-
ages. HIF-1 upregulation in pro-angiogenic
therapies could facilitate the formation of
fully matured vascularity.
Therefore, the understanding of the molecu-
lar mechanisms of HIF-1 activation will be
crucial for the development of new drugs act-
ing either as agonists or as antagonists of the
hypoxia response pathway. Possible targets
of future therapies could be not only HIF-1
itself but also the proteins mediating its stabi-
lization such as prolyl and asparaginyl
hydroxylases.
We are grateful to Dr. Alicja Józkowicz and
Prof. Aleksander Koj for useful comments.
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